BPL Medical Technologies is reported to be targeting revenue of ₹2,000 crore by 2032, with growth centered on critical-care equipment and medical imaging. The figure is a reported company ambition, not an independently verified forecast: the page announcing it could not be retrieved, and the other available sources do not confirm the target or its assumptions. The plan concerns BPL Medical Technologies, the medical-device business, not the similarly named BPL Limited.
What BPL is reported to be targeting
A Whalesbook search-result excerpt reports that BPL Medical Technologies aims to reach ₹2,000 crore in revenue by 2032. Because the announcing page was unavailable for verification, the figure should be read as a reported target rather than a confirmed company forecast. The available sources do not establish the assumptions behind it or provide an independently verified current-year revenue baseline.
As an Amazon Associate I earn from qualifying purchases.
CARE Ratings reported audited total operating income of ₹443 crore in FY23 and ₹496 crore in FY24. Those historical figures give a sense of scale, but they are not a current run rate and do not establish whether the 2032 ambition is achievable. Total operating income is also the measure CARE reported; it should not be treated as interchangeable with the reported revenue target without further accounting detail.
Which BPL company is involved
The company is BPL Medical Technologies, incorporated in 2013 and focused on medical devices. It is distinct from BPL Limited. CARE Ratings reported that MNI Ventures, part of the Manipal Group, acquired the full 67% stake previously held by Goldman Sachs entities in July 2024. This ownership information is dated to that transaction and does not by itself explain the growth target.
#1 Best Overall
Where the growth push is focused
Critical care
BPL’s documented critical-care portfolio includes ventilators, patient monitors, and anesthesia machines. In a February 2026 interview, managing director Dr Shravan Subhramanian said, “We are going deep into a couple of critical areas, especially critical care.” That statement describes the company’s stated strategic emphasis, not evidence of future sales or market share.
CEO Guruswamy Krishnamoorthy later described the BPL Vent 300 as supporting invasive ventilation, non-invasive ventilation, and high-flow nasal cannula therapy for adult, pediatric, and infant patients. These product-function details are the executive’s description; they are not independent clinical-performance validation.
Imaging
BPL’s documented imaging activity includes ultrasound and X-ray. Subhramanian said, “On the imaging side, we have been active in ultrasound and X-ray.” In the same February 2026 interview, he described a fully AI-enabled X-ray system with diagnostic software embedded in the machine and an acquisition of a South Korean company specializing in bone mineral analysis. Those are company interview claims; the available information does not establish the system’s diagnostic accuracy or clinical outcomes.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Respiratory diagnostics and connected health
The strategy described by Krishnamoorthy extends beyond individual devices. He said, “BPL’s next phase of growth is anchored in expanding its portfolio beyond medical equipment to offer integrated digital healthcare solutions.” He also identified “advanced imaging, critical care, patient monitoring, respiratory diagnostics, and connected digital health solutions” as opportunity areas.
The company has discussed a respiratory-diagnostics partnership with Jaeger Medical and a broader combination of devices, software, AI-enabled technology, and clinical workflows. Such connected offerings may broaden the portfolio, but the available sources do not quantify their revenue contribution or show how quickly they could scale.
What the financial context does—and does not—show
CARE Ratings’ audited operating-income figures increased from ₹443 crore in FY23 to ₹496 crore in FY24. They provide historical context for the reported ₹2,000 crore-by-2032 ambition, but they are not evidence that the target has been met or that the required growth path is secured. No independently verified audited current-year figure or detailed target model is established by the available sources.
CARE Ratings expected average operating-income growth of about 20% in FY26–27 in a 2025 press release, citing manufacturing ramp-up and new product introductions. That is the agency’s projection for those fiscal years, not a realized result or a company guarantee; it also does not verify the separate 2032 target.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Execution risks to watch
CARE Ratings identifies several factors that could affect performance:
Best Value
- Hospital capital spending: Demand for medical equipment depends in part on hospitals’ capital-expenditure plans, which can influence the timing of purchases.
- Foreign exchange: Currency movements can affect the business, particularly where costs or transactions are exposed to foreign currencies.
- Working capital: The business is working-capital intensive, making funding needs and cash conversion relevant as operations expand.
- Competition: BPL competes with established international companies in medical-device markets.
These risks matter because portfolio expansion and manufacturing growth require execution as well as demand. The reported target remains an ambition whose assumptions, current revenue base, and progress toward the 2032 endpoint are not independently established in the available information.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
